Milestone Pharmaceuticals Inc. MIST
Set alert
At close · Oct 30
After hours · Oct 30, 7:56 PM ET
- YTD
- -63.86%
- 1 year
- -61.17%
- Open
- 0.79
- Prev close
- 0.7896
- Mkt cap
- 90.88M
- Vol
- 730.16K
- Avg vol
- 1.35M
- EPS
- -0.68
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7259
- High
- 0.7997
- Forward P/E
- -2.15
- Beta
- 1.73
- Short ratio
- 2.46
- Inst. own
- 57.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.71
- 200-d avg
- 1.58
- 1y target
- 10.25
5D chart
Signals (114)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 4:00 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 4:00 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:35 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:10 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:05 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 1 day ago |
| RSI: Oversold | Oct 30, 1:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:55 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:50 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:25 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:00 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:10 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:35 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:30 PM | 2 days ago |
| RSI: Overbought | Oct 29, 12:15 PM | 2 days ago |
| RSI: Overbought | Oct 29, 11:55 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:00 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:25 PM | 3 days ago |
| RSI: Overbought | Oct 28, 2:15 PM | 3 days ago |
| RSI: Overbought | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:10 PM | 3 days ago |
| RSI: Overbought | Oct 28, 12:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 3 days ago |
| RSI: Overbought | Oct 28, 11:25 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 11:20 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:05 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:40 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:25 PM | 5 days ago |
| RSI: Oversold | Oct 26, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 5 days ago |
News
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
-
1 month ago benzinga.com
Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone
-
2 months ago benzinga.com
Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes' At European Society Of Cardiology Congress 2026
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced findings from a…
2 months ago benzinga.com
This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page for full details and stock recommendations.
-
2 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $3
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $3.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
-
2 months ago benzinga.com
Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 10.53 percent. This is a 5 percent decrease over…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $8 to $7.
5 months ago benzinga.com
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before the market opened.
5 months ago benzinga.com
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
5 months ago benzinga.com
Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial
Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
7 months ago benzinga.com
Why Milestone Pharma Stock Is Taking A Dive Today
EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.
-
7 months ago benzinga.com
Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 15.79 percent increase over losses of $(0.19) per share from…
-
7 months ago benzinga.com
Earnings Scheduled For March 20, 2026
Earnings Scheduled For March 20, 2026
7 months ago benzinga.com
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.
-
9 months ago benzinga.com
Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Commercial Product, Through US Retail Pharmacies
CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Implementation of a…
-
9 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $8 price target.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
10 months ago benzinga.com
AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Delivering The Newly Approved CARDAMYST
Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the…
-
10 months ago benzinga.com
Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.
-
10 months ago benzinga.com
TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target
TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and announces $8 price target.
-
10 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and raises the price target from $5 to $8.
10 months ago benzinga.com
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for PSVT in 30 years.
-
10 months ago benzinga.com
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved…
-
10 months ago benzinga.com
Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For Paroxysmal Supraventricular Tachycardia
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT…
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
11 months ago benzinga.com
Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 26.83 percent. This is a 14.29 percent increase over…
-
12 months ago benzinga.com
Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray, Consistently Showed Efficacy And Favorable Safety Profile Across Multiple Studies Comprising Global Development Program
Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that new data…
-
1 year ago benzinga.com
Wells Fargo Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces Price Target of $4
Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and announces Price Target of $4.
-
1 year ago benzinga.com
Milestone Pharmaceuticals Q2 EPS $(0.20) Misses $(0.17) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over…
1 year ago benzinga.com
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
Why Is Milestone Pharmaceuticals Stock Plunging On Friday?
FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.
1 year ago benzinga.com
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
-
1 year ago benzinga.com
Milestone Pharma Prices $52.5M Equity Offering With Warrants; Offering Is Expected To Close On Or About July 14, 2025
Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
HC Wainwright & Co. Assumes Milestone Pharmaceuticals at Buy, Announces Price Target of $5
HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announces Price Target of $5.
-
1 year ago benzinga.com
Milestone Pharmaceuticals Q1 EPS $(0.31) Misses $(0.18) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.18) by 72.22 percent. This is a 47.62 percent decrease over…
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $10
HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $25 to $10.
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $25 price target.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
1 year ago benzinga.com
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
2 years ago benzinga.com
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
-
3 years ago benzinga.com
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 135 companies reached new 52-week lows.